Immune Checkpoint Inhibitors and Novel Immunotherapy Approaches for Breast Cancer.
Curr Oncol Rep
; 24(12): 1801-1819, 2022 12.
Article
en En
| MEDLINE
| ID: mdl-36255603
ABSTRACT
PURPOSE OF REVIEW To critically review the existing evidence on immune checkpoint inhibitors (ICIs) in early-stage and metastatic breast cancer and discuss emerging strategies in the different breast cancer subtypes. RECENT FINDINGS:
Immunotherapy has become one of the major milestones in contemporary oncology, revolutionizing the treatment of multiple solid tumors. ICI agents combined with chemotherapy have demonstrated significant efficacy in both early-stage and metastatic triple-negative breast cancer. However, only a subgroup of patients responds to those agents and some associated toxicities, although infrequent, can be life-disabling. Emerging data from immunotherapy studies in advanced hormone receptor-positive (HR +) breast cancer as well as HER2-positive disease are arising with mixed results. Although breast cancer has not classically been considered a hot tumor, ICIs have proven to be effective in a subset of breast cancer patients. However, much remains to be learned, and the identification of new biomarkers beyond PD-L1 expression is essential not only to improve the efficacy of ICI but also to identify patients who can avoid them, together with their toxicities and costs.Palabras clave
Biomarkers; Breast cancer; Early stage; HER2-positive breast cancer; Hormone receptorpositive breast cancer; Immune checkpoint blockade; Immune checkpoint inhibitors; Immune response; Immunotherapy; Metastatic breast cancer; PD-1; PD-L1; Triple-negative breast cancer; Tumor mutational burden; Tumor subtype; Tumor-infiltrating lymphocytes
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias de la Mama Triple Negativas
/
Inhibidores de Puntos de Control Inmunológico
Tipo de estudio:
Prognostic_studies
Límite:
Humans
Idioma:
En
Revista:
Curr Oncol Rep
Asunto de la revista:
NEOPLASIAS
Año:
2022
Tipo del documento:
Article
País de afiliación:
España